NanoString Technologies, Inc. - NSTG STOCK NEWS

NanoString Technologies (NASDAQ:NSTG) reported record Q4 2021 revenue of $42 million, driven by strong sales of the GeoMx Digital Spatial Profiler. The company achieved nearly 50% year-on-year revenue growth for GeoMx, totaling $18 million in Q4 alone. For the full year, total revenue reached $144 million, marking a 29% increase. The company is seeing robust demand for its upcoming CosMx Spatial Molecular Imager, with 20 pre-orders secured. Cash reserves stand at approximately $350 million as of December 31, 2021.

NanoString Technologies (NASDAQ:NSTG) will present at the 40th Annual JP Morgan Healthcare Conference from January 10-13, 2022. CEO Brad Gray is scheduled to speak on January 12, 2022, at 3:00 PM PT. The presentation will be available via live webcast on the company's investor website, with a replay accessible one hour after the presentation and archived for 60 days. NanoString is recognized for its innovative life science tools, enabling advanced research such as the nCounter Analysis System and GeoMx Digital Spatial Profiler, among others.

NanoString Technologies, Inc. (NASDAQ:NSTG) announced its participation in the Stifel 2021 Virtual Healthcare Conference. CEO Brad Gray will present on November 15, 2021, at 4:40 PM ET. The live webcast, including slides, will be accessible via the investor section of their website at www.nanostring.com. A replay will be available one hour post-presentation and archived for 60 days. NanoString is known for its innovative life science tools, including the nCounter® Analysis System and GeoMx® Digital Spatial Profiler.

NanoString Technologies, Inc. (NASDAQ:NSTG) reported Q3 financial results for the period ending September 30, 2021, with product and service revenue of $36.9 million, a 23% year-over-year increase. Instrument revenues grew 13% to $14.5 million, while consumables revenue surged 32% to $18.0 million. The GeoMx DSP revenues reached $49 to $50 million in 2021, exceeding prior guidance. Despite growth, net loss for Q3 was $31.3 million. The company aims to bolster its market position with innovative Spatial Biology technologies like CosMx SMI.

NanoString Technologies has publicly released data from the CosMx™ Spatial Molecular Imager, marking the first high-plex, single-cell dataset from FFPE non-small cell lung cancer samples. This dataset includes over 800,000 single cells, ~260 million transcripts, and a spatially-resolved cell type map. The CosMx SMI technology allows researchers to visualize gene expression and proteins at single-cell resolution, promising new insights into disease mechanisms and treatment responses. The data and accompanying manuscript are accessible to the research community.

NanoString Technologies (NASDAQ: NSTG) recently announced a significant peer-reviewed study published in Cell, exploring anosmia, a COVID-19 symptom. The research analyzed 70 patient samples to determine the impact of SARS-CoV-2 on olfactory neurons using the GeoMx Digital Spatial Profiler. Findings revealed that while the virus does not directly infect olfactory sensory neurons, high viral loads reduce gene expression in neighboring cells. This research underscores the utility of spatial transcriptomics in understanding COVID-19's effects, marking a notable advancement in the field of life sciences.

Vizgen has appointed Dale Levitzke as Senior Vice President of Global Sales and Support, aiming to enhance its commercial reach for the MERSCOPE Platform.

Levitzke, with nearly 20 years in diagnostics sales, previously led NanoString's revenue growth from under $10MM to over $125MM. His experience will help Vizgen navigate the global market and expand distribution channels in 2022.

The MERSCOPE Platform offers significant insights into spatial genomics, with early uptake at leading institutions, reflecting strong demand in the burgeoning field of spatial biology.

NanoString Technologies (NASDAQ: NSTG) has launched the Spatial Organ Atlas, a vital resource that maps spatially resolved whole transcriptomes from six organs, including the kidney and pancreas. This initiative aims to provide researchers with insights into organ functions in health and disease, enhancing the utility of the GeoMx® Digital Spatial Profiler. The database is publicly accessible, offering downloadable datasets, interactive tools, and plans for continuous updates to include additional organs.

NanoString Technologies, a leader in life science tools, has launched the nCounter® ADC Development Panel to facilitate research in Antibody Drug Conjugates (ADCs). This new gene expression tool, developed with input from pharmaceutical experts, aims to provide comprehensive molecular insights necessary for addressing critical questions in oncology therapies. The panel can profile 770 genes and aids in understanding ADC mechanisms, including tumor targeting and resistance. Currently, there are 10 approved ADCs and over 80 in clinical trials, indicating the growing importance of this technology in cancer treatment.